Pure Bioscience Inc
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. Its technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. The comp… Read more
Pure Bioscience Inc (PURE) - Total Assets
Latest total assets as of January 2025: $574.00K USD
Based on the latest financial reports, Pure Bioscience Inc (PURE) holds total assets worth $574.00K USD as of January 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pure Bioscience Inc - Total Assets Trend (1996–2024)
This chart illustrates how Pure Bioscience Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pure Bioscience Inc - Asset Composition Analysis
Current Asset Composition (July 2024)
Pure Bioscience Inc's total assets of $574.00K consist of 98.4% current assets and 1.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.8% |
| Accounts Receivable | $298.00K | 36.4% |
| Inventory | $56.00K | 6.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Pure Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pure Bioscience Inc's current assets represent 98.4% of total assets in 2024, an increase from 37.5% in 1996.
- Cash Position: Cash and equivalents constituted 51.8% of total assets in 2024, up from 0.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 36.4% of total assets.
Pure Bioscience Inc Competitors by Total Assets
Key competitors of Pure Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥3.66 Billion |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$8.26 Billion |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
China | CN¥2.20 Billion |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥3.08 Billion |
|
Dencare (Chongqing) Oral Care Co. Ltd. A
SHE:001328
|
China | CN¥1.90 Billion |
|
Qingdao Kingking Applied Chemistry Co Ltd
SHE:002094
|
China | CN¥3.19 Billion |
|
C&S Paper Co Ltd
SHE:002511
|
China | CN¥9.17 Billion |
|
Anhui Deli Household Glass Co Ltd
SHE:002571
|
China | CN¥3.08 Billion |
Pure Bioscience Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Pure Bioscience Inc generates 2.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pure Bioscience Inc is currently not profitable relative to its asset base.
Pure Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 1.72 | 2.68 |
| Quick Ratio | 0.56 | 1.59 | 2.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-304.00K | $ 394.00K | $ 2.50 Million |
Pure Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Pure Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.57 |
| Latest Market Cap to Assets Ratio | 6.02 |
| Asset Growth Rate (YoY) | -55.2% |
| Total Assets | $818.00K |
| Market Capitalization | $4.93 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Pure Bioscience Inc's assets at a significant premium ( 6.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Pure Bioscience Inc's assets decreased by 55.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pure Bioscience Inc (1996–2024)
The table below shows the annual total assets of Pure Bioscience Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-07-31 | $818.00K | -55.18% |
| 2023-07-31 | $1.82 Million | -59.30% |
| 2022-07-31 | $4.48 Million | +4.21% |
| 2021-07-31 | $4.30 Million | -31.95% |
| 2020-07-31 | $6.32 Million | +227.28% |
| 2019-07-31 | $1.93 Million | -24.97% |
| 2018-07-31 | $2.58 Million | -32.75% |
| 2017-07-31 | $3.83 Million | -49.37% |
| 2016-07-31 | $7.56 Million | +131.89% |
| 2015-07-31 | $3.26 Million | +75.42% |
| 2014-07-31 | $1.86 Million | -9.84% |
| 2013-07-31 | $2.06 Million | -53.75% |
| 2012-07-31 | $4.46 Million | -13.40% |
| 2011-07-31 | $5.15 Million | -14.11% |
| 2010-07-31 | $5.99 Million | -21.64% |
| 2009-07-31 | $7.65 Million | -30.09% |
| 2008-07-31 | $10.94 Million | +125.03% |
| 2007-07-31 | $4.86 Million | -38.96% |
| 2006-07-31 | $7.97 Million | +140.35% |
| 2005-07-31 | $3.31 Million | -39.55% |
| 2004-07-31 | $5.48 Million | +20.74% |
| 2003-07-31 | $4.54 Million | 0.00% |
| 2002-07-31 | $4.54 Million | +11.64% |
| 2001-07-31 | $4.07 Million | -21.18% |
| 2000-07-31 | $5.16 Million | +28.99% |
| 1999-07-31 | $4.00 Million | +33.33% |
| 1998-07-31 | $3.00 Million | -16.67% |
| 1997-07-31 | $3.60 Million | +350.00% |
| 1996-07-31 | $800.00K | -- |